Naloxon Hameln (Naloxone Hydrochloride Dihydrate)

Naloxone binds competitively to μ‑opioid receptors without activating them, displacing opioid molecules that are causing sedation or respiratory depression. This blockade quickly restores normal neuronal signaling, allowing breathing and alertness to return.

The dose of Naloxon Hameln is determined by the prescribing clinician based on the severity of opioid toxicity, the route of administration, and patient factors. Healthcare professionals follow local protocols to decide the appropriate amount and frequency.

Safety data for naloxone in pregnancy and lactation are limited. The drug is generally considered low risk because it does not cross the placenta in significant amounts, but clinicians weigh potential benefits against unknown risks before use in pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Naloxon Hameln contains naloxone, the most widely used opioid antagonist. Compared with alternatives such as nalmefene, naloxone has a faster onset of action and a shorter half‑life, making it ideal for acute emergency reversal, whereas other agents may be preferred for longer‑duration management.

Naloxon Hameln should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the vial. If refrigeration is unavailable for a short period, the product may be kept at controlled room temperature, but potency could be affected.

Naloxon Hameln is supplied as a sterile injectable solution for intramuscular (IM) or intravenous (IV) injection. In emergency situations, a typical initial dose is given rapidly, and the patient is monitored for clinical response, with additional doses administered if needed.

Serious risks include acute hypertension, cardiac arrhythmias, pulmonary edema, and rare anaphylactic reactions. Because naloxone can precipitate rapid withdrawal in opioid‑dependent individuals, clinicians should be prepared to manage agitation, pain, or seizures that may follow reversal.

Naloxon Hameln is contraindicated in individuals with known hypersensitivity to naloxone or any component of the formulation. Caution is advised for patients with severe cardiovascular disease, as rapid opioid reversal can provoke hemodynamic instability.